|
Phase 1 study of the safety and efficacy of INCB050465 combined with obinutuzumab and bendamustine for relapsed or refractory (R/R) follicular lymphoma (FL) (CITADEL-102). |
|
|
Stock and Other Ownership Interests - Abbvie |
Consulting or Advisory Role - Bayer; Gilead Sciences |
Speakers' Bureau - Celgene; Gilead Sciences; Pharmacyclics |
Research Funding - Celgene; Gilead Sciences; Merck; Millennium; Pharmacyclics; Roche |
|
|
Consulting or Advisory Role - Incyte; Janssen; Roche; Sandoz |
Speakers' Bureau - Mundipharma; Roche |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Incyte; Novartis |
Stock and Other Ownership Interests - Incyte |
Research Funding - Incyte; Novartis |
Travel, Accommodations, Expenses - Incyte; Novartis |
|
|
No Relationships to Disclose |